ArticleScientific reports2021
In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Adaptation mechanisms of Clostridioides difficile to auranofin and its impact on human gut microbiota.NPJ biofilms and microbiomes · 2024Article
- The state of play of rodent models for the study ofJournal of medical microbiology · 2024Review
- Article
- Article
- Gut microbiome changes in mouse, Mongolian gerbil, and hamster models followingFrontiers in microbiology · 2024Article
- Inhibition of selenoprotein synthesis is not the mechanism by which auranofin inhibits growth of Clostridioides difficile.Scientific reports · 2023Article
- In vivo efficacy of acetazolamide in a mouse model of Neisseria gonorrhoeae infection.Microbial pathogenesis · 2022Article
- In Vitro and In Vivo Anti-Journal of microbiology and biotechnology · 2022Article
- Auranofin exerts antibacterial activity against Neisseria gonorrhoeae in a female mouse model of genital tract infection.PloS one · 2022Article
- 2'FL and LNnT Exert Antipathogenic Effects againstPathogens (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Clostridioides difficile infections (CDIs) are an urgent public health threat worldwide and are a leading cause of morbidity and mortality in healthcare settings. The increasing incidence and severity of infections combined with the scarcity of effective anti-CDI agents has made treatment of CDI very challenging. Therefore, development of new, effective anticlostridial agents remains a high priority. The current study investigated the in vivo efficacy of auranofin in a CDI hamster model. All hamsters treated with auranofin (5 mg/kg) survived a lethal challenge with C. difficile. Furthermore, auranofin (5 mg/kg) was as effective as vancomycin, the drug of choice for treatment of CDIs, against relapsing CDI. Furthermore, auranofin (5 mg/kg) generated a 3.15-log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.